Article Content

BRAIN/CNS TUMORS

P2/3 Randomized Study of Toca 511 & Toca FC Versus SOC in Subjects Undergoing Surgery for Recurrent GBM/AA

  
Figure. No caption a... - Click to enlarge in new windowFigure. No caption available.

Phase: Phase III, Phase II

 

Type: Treatment

 

Age: 18 to 75

 

Trial IDs: Tg 511-15-01, NCI-2015-01577, NCT02414165

 

Ponatinib Hydrochloride in Treating Patients with Bevacizumab-Refractory Glioblastoma

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 15-163, NCI-2015-01746, NCT02478164

 

Correlation between Genetic and Imaging Information in Patients with Newly Diagnosed Glioblastoma before Surgery

 

Phase: No phase specified

 

Type: Biomarker/Laboratory analysis, Diagnostic

 

Age: Not specified

 

Trial IDs: OSU-15019, NCI-2015-00873, NCT02590497

 

DNX-2401 With Interferon Gamma for Recurrent Glioblastoma or Gliosarcoma Brain Tumors

 

Phase: Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 2401BT-IFN-001, NCI-2014-01929, NCT02197169

 

Neoantigen-based Glioblastoma Vaccine and Poly-ICLC Vaccine in Treating Patients with Newly Diagnosed Glioblastoma

 

Phase: No phase specified

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 201510022, NCI-2015-01776, NCT02510950

 

BREAST CANCER

SANDPIPER Study: A Study Of Taselisib + Fulvestrant Versus Placebo + Fulvestrant In Patients With Advanced or Metastatic Breast Cancer Who Have Disease Recurrence or Progression During or After Aromatase Inhibitor Therapy

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over, postmenopausal

 

Trial IDs: GO29058, NCI-2015-01649, 2014-003185-25, NCT02340221

 

Boost Radiation Therapy before Surgery in Treating Patients with Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: Not specified

 

Trial IDs: Pro00063936, NCI-2015-01625, NCT02482389

 

Prophylactic Topical Agents in Reducing Radiation-Induced Dermatitis in Patients with Non-inflammatory Breast Cancer or Breast Cancer In Situ

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Supportive care

 

Age: 21 and over

 

Trial IDs: URCC14079, NCI-2015-00869, NCT02556632

 

Palbociclib and Bazedoxifene in Treating Patients with Hormone Receptor Positive Locally Advanced or Metastatic Breast Cancer That Cannot Be Removed by Surgery

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 15-060, NCI-2015-01604, NCT02448771

 

A Study of Ipatasertib (GDC-0068) in Combination With Paclitaxel as Neoadjuvant Treatment for Patients With Early Stage Triple Negative Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: GO29505, NCI-2015-01653, 2014-003029-16, NCT02301988

 

Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients with Triple Negative Stage II-III Breast Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 041401, NCI-2014-02029, NCT02315196

 

CERVICAL CANCER

Image Guided Hypofractionated Radiation Therapy in Treating Patients with Stage IB-IVB Cervical Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: STU 082013-064, NCI-2015-01672, NCT02045433

 

COLORECTAL CANCER

Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery

 

Phase: Phase III, Phase II

 

Type: Supportive care

 

Age: 18 and over

 

Trial IDs: 14-114, NCI-2015-01705, NCT02195232

 

Intensity Modulated Radiation Therapy and Quality of Life in Patients With Rectal Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 09-157, NCI-2010-01327, NCT01148056

 

Combination Chemotherapy and Bevacizumab with or without PRI-724 in Treating Patients with Newly Diagnosed Metastatic Colorectal Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 3C-13-3, NCI-2015-00436, NCT02413853

 

Study of Pembrolizumab (MK-3475) as Monotherapy in Participants With Previously-Treated Locally Advanced Unresectable or Metastatic Colorectal Cancer (MK-3475-164/KEYNOTE-164)

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 3475-164, NCI-2015-01721, 2015-001852-32, NCT02460198

 

Health Education Materials With or Without a Physical Activity Program for Patients Who Have Undergone Treatment for High-Risk Stage II or Stage III Colon Cancer

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Educational/Counseling/Training

 

Age: 18 and over

 

Trial IDs: CO21, NCI-2015-01662, CAN-NCIC-CO21, CDR0000629834, NCT00819208

 

Study of LGX818 and Cetuximab or LGX818, BYL719, and Cetuximab in BRAF Mutant Metastatic Colorectal Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: CLGX818X2103, NCI-2013-02457, 2012-002138-35, NCT01719380

 

ESOPHAGEAL CANCER

Regorafenib in Treating Patients with Locally Advanced Cancer of the Esophagus or Gastroesophageal Junction Who Have Completed Chemoradiation Therapy and Surgery

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: RU021212I, NCI-2015-01699, NCI-2014-01962, NCT02234180

 

HEAD & NECK/ORAL CANCER

A Phase Ib/II Study of BYL719 and Cetuximab in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: CBYL719X2104, NCI-2013-00766, 2011-006017-34, NCT01602315

 

Pembrolizumab and Vorinostat in Treating Patients with Recurrent Squamous Cell Head and Neck Cancer or Salivary Gland Cancer That Is Metastatic and/or Cannot Be Removed by Surgery

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 9383, NCI-2015-01310, MK-3475, NCT02538510

 

Hypofractionated Radiation Therapy Followed by Surgery in Treating Patients with Advanced Squamous Cell Carcinoma of the Oral Cavity

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 031401, NCI-2014-02215, NCT02295540

 

KIDNEY CANCER

High-Dose Aldesleukin and Stereotactic Body Radiation Therapy in Treating Patients with Metastatic Kidney Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: STU 012013-041, NCI-2015-01670, NCT01896271

 

LEUKEMIA/LYMPHOMA/MDS

Efficacy and Safety of Idelalisib in Combination With Obinutuzumab Compared to Chlorambucil in Combination With Obinutuzumab for Previously Untreated Chronic Lymphocytic Leukemia

 

Phase: Phase III

 

Type: Treatment

 

Age: 65 and over

 

Trial IDs: GS-US-312-0118, NCI-2015-01760, 2013-004551-20, NCT01980875

 

Treatment for Advanced B-Cell Lymphoma

 

Phase: Phase II

 

Type: Treatment

 

Age: 3 to 31

 

Trial IDs: NYMC-157, NCI-2015-01702, L 10,753, NCT01859819

 

Combination Chemotherapy, Rituximab, and Ixazomib Citrate in Treating Patients with Non-Hodgkin Lymphoma

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: NU 14H09, NCI-2015-00400, STU00200596, X16042, NCT02481310

 

Brentuximab Vedotin, Doxorubicin Hydrochloride, and Dacarbazine in Treating Patients with Previously Untreated Stage I-IIA Non-bulky Classical Hodgkin Lymphoma

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 15-196, NCI-2015-01592, 35-IST-029, NCT02505269

 

CIP-613, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients with Relapsed or Refractory Acute Myeloid Leukemia or Granulocytic Sarcoma

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CCCWFU 22215, NCI-2015-01002, IRB00033779, NCT02484391

 

Combination Chemotherapy with or without Rituximab, Imatinib Mesylate, or Dasatinib in Treating Patients with Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 2008-0598, NCI-2011-00861, NCT01319981

 

AT13387 in Treating Patients with Relapsed or Refractory Anaplastic Large Cell Lymphoma, Mantle Cell Lymphoma, or Diffuse Large B-cell Lymphoma

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 9875, NCI-2015-01681, NCT02572453

 

LIVER CANCER

A Study to Evaluate the Safety and Efficacy of Ombitasvir/Paritaprevir/r With or Without Dasabuvir and With or Without Ribavirin in Chronic Hepatitis C Virus Genotype 1 or 4 Infected Adults With Successfully Treated Early Stage Hepatocellular Carcinoma

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: M14-726, NCI-2015-01664, 2015-001049-10, NCT02504099

 

Phase Ib/2, Multicenter, Dose Escalation Study of DCR-MYC in Patients With Hepatocellular Carcinoma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: Over 18

 

Trial IDs: DCR-MYC-102, NCI-2015-01659, NCT02314052

 

LUNG CANCER/MESOTHELIOMA

Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery

 

Phase: Phase III, Phase II

 

Type: Supportive care

 

Age: 18 and over

 

Trial IDs: 14-114, NCI-2015-01705, NCT02195232

 

Ceritinib and Stereotactic Ablative Radiation Therapy in Treating Patients with ALK-Rearranged Metastatic Lung Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 042015-076, NCI-2015-01632, NCT02513667

 

Olaparib and Temozolomide in Treating Patients with Recurrent Small Cell Lung Cancer

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 15-121, NCI-2015-01724, NCT02446704

 

A Phase III Study of MPDL3280A (Anti-PD-L1 Antibody) in Combination With Carboplatin + Nab-Paclitaxel in Patients With Non-Squamous Non-Small Cell Lung Cancer [IMpower 130]

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: GO29537, NCI-2015-01602, 2014-003206-32, NCT02367781

 

Alectinib and Bevacizumab in Treating Patients with ALK-positive Stage IIIB-IV Non-small Cell Lung Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 15-055, NCI-2015-01704, NCT02521051

 

AZD1775 Plus Carboplatin-Paclitaxel in Squamous Cell Lung Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: MCC-18304, NCI-2015-01598, 15.06.0034, 18304, NCT02513563

 

A Comparative Study of MPDL3280A (Anti-PDL1 Antibody) With Cisplatin or Carboplatin + Pemetrexed in Patients With Stage IV Non-Squamous Non-Small Cell Lung Cancer (NSCLC) [IMpower 110]

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: GO29431, NCI-2015-01580, 2014-003083-21, NCT02409342

 

Study of Efficacy and Safety of Nivolumab in Combination With EGF816 and of Nivolumab in Combination With INC280 in Patients With Previously Treated Non-small Cell Lung Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: CEGF816X2201C, NCI-2015-01626, 2014-003731-20, NCT02323126

 

Sublobar Resection or Stereotactic Ablative Radiotherapy in Treating Patients with Stage I Non-small Cell Lung Cancer

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: STU 022015-069, NCI-2015-01676, NCT02468024

 

Study to Assess Safety and Efficacy of Atezolizumab (MPDL3280A) Compared to Best Supportive Care Following Chemotherapy in Patients With Lung Cancer

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: GO29527, NCI-2015-01731, NCT02486718

 

Study of Safety and Efficacy of LEE011 and Ceritinib in Patients With ALK-positive Non-small Cell Lung Cancer.

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CLEE011X2110C, NCI-2015-01657, NCT02292550

 

Nintedanib (BIBF 1120) in Mesothelioma

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 1199.93, NCI-2013-01643, 2012-005201-48, NCT01907100

 

Study of the Safety and Efficacy of Amatuximab in Combination With Pemetrexed and Cisplatin in Subjects With Unresectable Malignant Pleural Mesothelioma (MPM).

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: MORAb-009-201, NCI-2015-01754, NCT02357147

 

MELANOMA

A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: PLX108-14, NCI-2015-01614, KEYNOTE-103, NCT02452424

 

Trametinib in Treating Patients with Advanced Melanoma with BRAF Non-V600 Mutations

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: VICC MEL 1457, NCI-2014-02185, GSK1120212, MEL1457, NCT02296112

 

Pembrolizumab in Treating Patients with Advanced Uveal Melanoma

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: MEL1486, NCI-2015-00020, VICCMEL1486, NCT02359851

 

MYELOMA

A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CR104761, NCI-2015-01729, 2014-002272-88, 54767414MMY3007, NCT02195479

 

Study of Ibrutinib in Combination With Pomalidomide (Pomalyst(TM)) and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: PCYC-1138-CA, NCI-2015-01756, PCI-32765, NCT02548962

 

Standard-Dose Lenalidomide, Bortezomib, and Dexamethasone or High-Dose Lenalidomide, Bortezomib, and Dexamethasone Followed by Peripheral Blood Stem Cell Transplant in Treating Patients with Multiple Myeloma

 

Phase: Phase III

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 to 65

 

Trial IDs: 10-106, NCI-2010-02211, IFM/DFCI 2009, NCT01208662

 

Phase 1b Study of Carfilzomib Administered Once Weekly in Combination With Lenalidomide and Dexamethasone in Subjects With Multiple Myeloma

 

Phase: Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: CFZ013, NCI-2015-01611, NCT02335983

 

A Study to Evaluate the Safety and Pharmacokinetics of SAR650984 in Patients With Multiple Myeloma

 

Phase: Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: TED14154, NCI-2015-01696, U1111-1163-1073, NCT02514668

 

Regulatory T-cell Depletion before Stem Cell Transplant in Treating Patients with Multiple Myeloma

 

Phase: No phase specified

 

Type: Supportive care, Treatment

 

Age: 21 to 70

 

Trial IDs: 10-551-B, NCI-2015-01660, NCT01526096

 

OVARIAN CANCER

Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in Subjects With Newly Diagnosed Stage III or IV, High-grade Serous, Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: M13-694, NCI-2015-01623, 2014-005070-11, NCT02470585

 

Nivolumab with or without Ipilimumab in Treating Patients with Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: NRG-GY003, NCI-2014-02424, 9698, NCT02498600

 

Phase 1/2a Two-Arm Dose-Escalation Study of BAX69 in Subjects With Malignant Ascites of Ovarian Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 391402, NCI-2015-01741, NCT02540356

 

Tivozanib in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: NU12G11, NCI-2013-00748, STU00073756, NCT01853644

 

PANCREATIC CANCER

Isoquercetin in Preventing Venous Thromboembolic Events in Patients with Pancreatic Cancer, Non-small Cell Lung Cancer, or Colorectal Cancer That is Advanced or Cannot Be Removed by Surgery

 

Phase: Phase III, Phase II

 

Type: Supportive care

 

Age: 18 and over

 

Trial IDs: 14-114, NCI-2015-01705, NCT02195232

 

Study of Ibrutinib vs Placebo, in Combination With Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

 

Phase: Phase III, Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: PCYC-1137-CA, NCI-2015-01722, NCT02436668

 

Immunotherapy and SBRT Study in Borderline Resectable Pancreatic Cancer

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: NLG0605, NCI-2015-01697, 1409-1350, NCT02405585

 

Stereotactic Body Radiation Therapy in Treating Patients with Pancreatic or Ampulla of Vater Cancer That Cannot Be Removed by Surgery

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 16866B, NCI-2015-01656, NCT01342354

 

S1505: Combination Chemotherapy or Gemcitabine Hydrochloride and Paclitaxel Albumin-Stabilized Nanoparticle Formulation before Surgery in Treating Patients with Pancreatic Cancer That Can Be Removed by Surgery

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 to 75

 

Trial IDs: S1505, NCI-2015-01236, NCT02562716

 

PEDIATRIC CANCERS

UVADEX(R) and ECP for the Treatment of Pediatric Patients With Steroid Refractory Acute Graft Versus Host Disease

 

Phase: Phase III

 

Type: Treatment

 

Age: 1 to 21

 

Trial IDs: TKS-2014-001, NCI-2015-01646, NCT02524847

 

A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, and Preliminary Efficacy of MPDL3280A (Anti-PD-L1 Antibody) in Pediatric and Young Adult Participants With Solid Tumors

 

Phase: Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 30 and under

 

Trial IDs: GO29664, NCI-2015-01687, 2014-004697-41, NCT02541604

 

PROSTATE CANCER

Enzalutamide in Androgen Deprivation Therapy With Radiation Therapy for High Risk, Clinically Localized, Prostate Cancer

 

Phase: Phase III

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: ANZUP1303, NCI-2015-01658, ACTRN12614000126617, NCT02446444

 

Enzalutamide and Leuprolide Acetate after Radiation Therapy in Treating Patients with High-Risk Prostate Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 15558, NCI-2015-01757, 147883, CC #15558, NCI-2015-01748, NCT02508636

 

Multiparametric MRI-Based Active Surveillance in Monitoring Patients with Low Risk Prostate Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Diagnostic

 

Age: 40 and over

 

Trial IDs: MCC-14-10633, NCI-2015-01739, 02147, NCT02564549

 

Enzalutamide and Cabazitaxel in Treating Patients with Metastatic, Hormone-Resistant Prostate Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: IRB00011227, NCI-2015-01103, 11227, CRS00001390, NCT02522715

 

LY2452473 in Improving Symptom Management in Patients with Undetectable PSA after Surgery for Prostate Cancer

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Supportive care

 

Age: 19 and over

 

Trial IDs: 15-120, NCI-2015-01601, NCT02499497

 

Rectal Spacer in Reducing Radiation Toxicity to Rectum in Patients with Low-Risk Prostate Cancer Undergoing Stereotactic Body Radiation Therapy

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: STU 092013-013, NCI-2014-02121, NCT02353832

 

Metformin Hydrochloride and Aspirin in Treating Patients with Hormone-Dependent Prostate Cancer That Has Progressed after Surgery or Radiation Therapy

 

Phase: Phase II

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 081501, NCI-2015-00397, NCT02420652

 

Safety, Preliminary Efficacy and Pharmacokinetics of ASN001 in Metastatic Castrate Resistant Prostate Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: ASN001-101, NCI-2015-01712, NCT02349139

 

Sirolimus, Docetaxel, and Carboplatin in Treating Patients with Metastatic Hormone-Resistant Prostate Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 9388, NCI-2015-01478, NCT02565901

 

THYROID CANCER

TORC1/2 Inhibitor INK128 in Treating Patients with Newly Diagnosed or Refractory/Metastatic Anaplastic Thyroid Cancer

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: 14-223, NCI-2015-01607, NCT02244463

 

MISCELLANEOUS/MULTIPLE/OTHER

Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

 

Phase: Phase III

 

Type: Natural history/Epidemiology

 

Age: 18 to 70

 

Trial IDs: BMTCTN07LT, NCI-2015-01752, U01HL069294-05, NCT02322320

 

A Study Evaluating the Safety and Efficacy of the LentiGlobin(R) BB305 Drug Product in Beta-Thalassemia Major Subjects

 

Phase: Phase II, Phase I

 

Type: Treatment

 

Age: 12 to 35

 

Trial IDs: HGB-204, NCI-2015-01667, NCT01745120

 

PLX3397 and Sirolimus in Treating Patients with Sarcoma or Malignant Peripheral Nerve Sheath Tumors That Cannot Be Removed by Surgery

 

Phase: Phase II, Phase I

 

Type: Biomarker/Laboratory analysis, Treatment

 

Age: 18 and over

 

Trial IDs: AAAO6059, NCI-2015-01768, NCT02584647

 

Stereotactic Body Radiation Therapy and Vertebroplasty in Treating Pain in Patients with Localized Spinal Metastasis

 

Phase: Phase II

 

Type: Supportive care, Treatment

 

Age: 18 and over

 

Trial IDs: STU 072010-134, NCI-2015-01674, SCCC-112008-022, 112008-022, SBRT Spine, NCT00855803

 

Imetelstat Sodium in Treating Patients With Primary or Secondary Myelofibrosis

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: CR107110, NCI-2014-02218, CP14B019, NCT01731951

 

Topical Menthol Cream in Reducing Pain in Patients with Chemotherapy Induced Peripheral Neuropathy

 

Phase: Phase II

 

Type: Supportive care

 

Age: 18 and over

 

Trial IDs: AAAL2664, NCI-2015-01613, CF-AAAM4210, NCT01855607

 

Idelalisib in Treating Patients with Relapsed or Refractory Waldenstrom Macroglobulinemia

 

Phase: Phase II

 

Type: Treatment

 

Age: 18 and over

 

Trial IDs: 15-040, NCI-2015-01605, NCT02439138

 

Gallium Ga 68-Edotreotide PET/CT in Imaging Patients with Somatostatin Receptor Positive Tumors

 

Phase: Phase II

 

Type: Diagnostic

 

Age: 6 months and over

 

Trial IDs: 201503708, NCI-2015-01588, NCT02441062